Regulatory Impact Of CSR Uncertainty Still To Come

October 10, 2017 at 7:47 PM
Regardless of what the Trump administration and GOP-led Congress ultimately decide about the cost-sharing reduction subsidies for low-income people who buy their insurance on the individual market, the ongoing uncertainty foreshadows a regulatory and operational mess down the road, several health policy experts, officials and consumer advocates say. Open enrollment will start in less than a month, and now that insurers have filed their final rates any CSR scenario comes with problems. In some cases, consumers could ultimately pay the...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.